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ECONOMIC EVALUATION OF DIAGNOSTIC STRATEGIES IN
PATIENTS WITH SUSPECTED CORONARY ARTERY DISEASE
(CAD) IN THE UK
Ratcliffe A1, Barwell T1, Chambers MG2
1Abacus International, BICESTER, OXON, UK, 2GE Healthcare,
Buckinghamshire, UK
OBJECTIVE: The early identiﬁcation of coronary artery disease
CAD is important in preventing subsequent premature mortal-
ity and disability, and potentially reducing the health care burden
associated with advanced disease. The objective of this study was
to evaluate the cost-effectiveness of myocardial perfusion scintig-
raphy (MPS) for patients with suspected chronic CAD in the UK.
METHOD: A decision-analytic model was developed to repre-
sent the diagnosis and management of patients with suspected
XCAD. A “diagnostic” module represented alternative diagnos-
tic strategies based on combinations of exercise ECG (ExECG),
MPS and coronary angiography (CA). A ‘treatment’ module rep-
resented initial patient management, based on diagnostic results.
Finally, subsequent patient experience (mortality, future MIs and
revascularisation procedures) according to severity of disease
and therapy at outset was represented as a Markov process.
Event risks, therapy effectiveness (risk reductions), diagnostic
accuracy and risks were obtained from published studies. Test
and intervention costs were based on NHS reference values.
Long-term costs of patient management for patients with CAD
in the UK, and health state utilities were based on published
values. The model was used to test parameter assumptions,
including duration of therapy effectiveness (base case: 5–10
years) and delay to diagnosis of false negatives (those missed in
initial work-up: base case 1 year). RESULTS: Compared with
ExECG, MPS was cost-effective when the underlying risk of
CAD was <50% (cost saving at <30%). Compared with a strat-
egy of no testing MPS was cost-effective at an underlying risk of
>20%. At ≥80% risk direct CA was cost saving and more effec-
tive than alternative diagnostic strategies. Adding MPS as a
second-line test for patients positive or indeterminate on ExECG
was cost-effective for intermediate risk patients. CONCLU-
SION: MPS is likely to be an economically attractive ﬁrst-line or
second-line test in the diagnostic work-up of symptomatic
patients with intermediate risk of chronic CAD.
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LOSARTAN-BASED VERSUS ATENOLOL-BASED THERAPY IN
PATIENTS WITH HYPERTENSION AND LEFT VENTRICULAR
HYPERTROPHY: AN ECONOMIC EVALUATION OF THE
LOSARTAN INTERVENTION FOR ENDPOINT REDUCTION IN
HYPERTENSION (LIFE) STUDY FOR GERMANY
Krobot KJ1, Carides GW2,Wagner A1, Burke TA3
1MSD Sharp & Dohme GmbH, Haar, Germany, 2Merck & Co., Inc,
Upper Gwynedd, PA, USA, 3Merck & Co., Inc, Whitehouse Station, NJ,
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OBJECTIVE: The Losartan Intervention For Endpoint Reduc-
tion in Hypertension study (LIFE) was a double-masked, ran-
domized trial of losartan versus atenolol in 9193 patients with
essential hypertension and left ventricular hypertrophy ascer-
tained by electrocardiography. Losartan reduced the primary
composite end point of cardiovascular death, myocardial infarc-
tion, or stroke by 13% (p = 0.021) and reduced the risk of stroke
by 25% (p = 0.001), despite a comparable degree of blood pres-
sure control. We aimed to evaluate the cost-effectiveness of losar-
tan compared with atenolol in LIFE from a German health care
system’s perspective. METHODS: Discounted life expectancy
with stroke, study medication use and quality of life by stroke
status were estimated directly from the LIFE trial. The trial data
were supplemented with data from Germany on discounted
direct lifetime costs of stroke (€43,129) and discounted life
expectancy in individuals without stroke. Quality-adjusted life
years were estimated by weighting life years by health-related
quality of life as measured by visual analogue scale data collected
in the LIFE trial. RESULTS: The lower cumulative incidence 
of stroke for losartan at 5.5 years (4.9%) as compared with
atenolol (6.5%) (p = 0.003) was estimated to reduce stroke-
related direct costs by €691 per patient and thus to offset 52%
of the incremental medication cost in patients receiving losartan.
The cost per quality-adjusted life year gained was €23,630 (95%
CI: −1276 to 95,115) for losartan-based versus atenolol-based
treatment. CONCLUSION: The clinical beneﬁt of losartan in
Germany is achieved at a cost well within accepted thresholds
for cost-effectiveness. A substantial proportion of the incremen-
tal cost for losartan is offset due to strokes prevented.
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COST-UTILITY ANALYSIS OF EPROSARTAN COMPARED TO
ENALAPRIL AND RAMIPRIL IN THE TREATMENT OF
MODERATE TO SEVERE HYPERTENSION IN SWEDEN
Lindgren P1, Schwander B2, Zöllner Y3, Jönsson B4
1Stockholm Health Economics, Stockholm, Sweden, 2Analytica
International, Loerrach, Germany, 3Solvay Pharmaceuticals GmbH,
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OBJECTIVES: To assess the cost-utility of Eprosartan (Teveten)
compared to the two most commonly used ACE-inhibitors in
Sweden. METHODS: Cost-effectiveness from the societal and
health-care payer perspective was evaluated using Monte Carlo-
simulation within a Markov framework. The risk of cardiovas-
cular and cerebrovascular events was based on the Framingham
study. Costs (2005 Swedish Kronor, SEK, 1€ = 9,22 SEK) and
utilities were based on published sources. The treatments effect
on systolic blood pressure (SBP) was taken from randomized
clinical trials and the risk reduction due to lower SBP was based
on metaanalysis. Treatment lasted for 5 years and patients were
followed for the remainder of their life. 3% discounting of costs
and effects was applied. RESULTS: From the health-care payer
perspective, the cost-effectiveness compared to Enalapril ranged
from 226,098 SEK/QALY for a 40 year-old non-diabetic cohort
with 50% males (corresponding to a 5-year risk of 4.4%) to
35,253 SEK/QALY for 80-year olds with diabetes (correspond-
ing to a 5-year risk of 41.7%). The corresponding ﬁgures com-
pared to Ramipril was 143,857 SEK/QALY—10,263 SEK/
QALY. From a societal perspective (including cost in added years
of life) the ﬁgures were 176,237 SEK/QALY—283,882 SEK/
QALY and 93,996 SEK/QALY—258,891 SEK/QALY. CON-
CLUSIONS: The incremental cost-effectiveness ratios all fall
below the commonly used threshold value of 500,000 SEK per
QALY, even if costs in added years of life are included which
gives higher ratios for treatments that extend life in older age
groups. Eprosartan thus appears to be a cost-effective strategy
compared to Enalapril or Ramipril.
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OBJECTIVES: To assess the cost-effectiveness, from the UK
NHS perspective, of magnetic resonance angiography (MRA),
duplex ultrasound (DUS) and computed tomography (CT) com-
pared with contrast angiography (CA) in assessing the extent and
location of stenosis and subsequently formulating a treatment
plan for patients with peripheral arterial disease (PAD).
METHODS: A probabilistic decision tree was developed in order
to estimate the cost per QALY (in £2004) associated with each
diagnostic method for assessment of the whole leg, and the arter-
ies above and below the knee. Input parameters were obtained
from a systematic review, other published sources and expert
opinion. Lack of data to extrapolate the results to a longer period
led to consideration of a 1-year time horizon, therefore dis-
counting was not performed. RESULTS: DUS was the dominant
strategy for the assessment of the whole leg, with a cost per
QALY of £13,646. MRA appeared to be more cost-effective for
assessment of the arteries above the knee, with a cost-per-QALY
equal to £8628 with 2D-TOF MRA, and an incremental cost per
additional QALY equal to £37,024 when 2D-TOF MRA was
compared to DUS. For below the knee comparisons, results were
uncertain, with DUS being more likely to be cost-effective at
commonly accepted cost-per-QALY threshold values. CON-
CLUSIONS: The cost-effectiveness of the diagnostic tests was
dependent on the area of the leg being assessed, with DUS being
dominant for comparisons of the whole leg and cost-effective for
below the knee comparisons, and MRA being cost-effective for
above the knee assessments.
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ECONOMIC EVALUATION OF DRUG ELUTING STENTS:
COST-UTILITY ANALYSIS
Bischof M, Briel M, Bucher HC, Nordmann A
University Hospital Basel, Basel, BS, Switzerland
OBJECTIVES: Drug eluting stents (DES) are more effective than
bare metal stents (BMS) in preventing angiographic and clinical
restenosis. Within this study the cost-effectiveness of sirolimus
(SES) and paclitaxel eluting stents (PES) compared to BMS was
estimated for a UK setting with data from a meta-analysis.
METHODS: A probabilistic Markov model was constructed.
The model includes events observed in clinical trials (MI, revas-
cularisation, CABG) and the health states heart failure and
stroke. The meta-analysis data comprised 3-year follow-up data
from randomized controlled trials. Probability distributions were
ﬁtted to all transition probability, cost and quality of life (QoL)
parameters. Univariate sensitivity analysis was performed on
several parameters. Effects and costs were discounted at 3%, the
time horizon was 3 years and the number of stents was 1.27 per
patient. A health care perspective was adopted. QoL data was
obtained from published studies. RESULTS: The incremental
costs for SES patients are €712 (95% CI: −2431–1715) and
€1101 (95% CI: 150–1493) for PES patients. DES yield less
QALYs than BMS with −0.0156 incremental QALYs (95% CI:
−0.2652–0.2302) per SES patient and −0.0077 incremental
QALYS (95% CI: −0.0777–0.06643) per PES patient compared
to BMS patients. At a threshold level of Euros 50’000 per QALY
the incremental net monetary beneﬁt per SES patient is €−1492
(95% CI: −14213–10766) and €−1484 (95% CI: −5004–2273)
per PES patient. At the same threshold level SES have a 35%
probability of being cost-effective, PES have a probability of
17% of being cost-effective. CONCLUSIONS: Three-year
follow up data show that DES are less effective than BMS when
mortality is taken into account. Given the higher costs per DES
patient, DES are dominated by BMS. Althoug DES show
favourable results over BMS concerning revascularisation rates,
they are not cost-effective.
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ESTIMATION OF THE PRESENCE OF CARDIOVASCULAR
EVENTS AND DIRECT COSTS ASSOCIATED WITH CHRONIC
OBSTRUCTIVE PULMONARY DISEASE IN AN AMBULATORY
SETTING
Sicras A1, Navarro R1, F Bobadilla J2, García M3, Soto J2
1Badalona Servicios Asistenciales, Badalona, Barcelona, Spain, 2Pﬁzer
Spain, Alcobendas, Madrid, Spain, 3Euroclin Institute, Alcobendas,
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OBJECTIVE: To determine the presence of cardiovascular events
(CVEs) and their association with the main cardiovascular risk
factors (CVRFs) and resource utilization parameters (direct
costs) in subjects with chronic obstructive pulmonary disease
(COPD) in different Spanish primary care centers. METHODS:
A retrospective-multicenter design was adopted, with inclusion
of the patients seen for COPD (ICPC:R95) by four primary care
teams and two hospitals during 2004. The main measures were:
age-sex, cardiovascular antecedents (ischemic heart disease
[IHD], cerebrovascular accident, hypertension, dyslipidemia,
diabetes mellitus, smoking, obesity) and other co-morbidities,
clinical parameters (FEV1, BMI), resources utilization (comple-
mentary tests, pharmaceutical prescription, specialist referral,
physician visits, hospitalizations and emergency-room visits,
ambulatory care) and costs (semiﬁxed and direct). A logistic
regression analysis was made to ﬁt the model. The costs were
contrasted by covariance analysis (ANCOVA-marginal means).
Data were analyzed using SPSS-v12 and p values of <0.05 were
taken as the level of statistical signiﬁcance. RESULTS: Nine-
hundred patients were seen for COPD; mean age 70.4 ± 9.8 years
and 85.3% were males. Around 19.0% (n = 171) had undergone
a CVE (CI: 16.4–21.6%); 15.1% with IHD. The main CVRFs
were: 44.1%-hypertension, 36.2%-obesity, 31.9%-dyslipidemia,
23.6%-diabetes and 22.7%-smoking. The mean morbidity/
patient/year was 10.1 ± 4.2 with CVEs vs. 8.3 ± 4.3 (p = 0.000);
the clinical parameters studied (FEV1, BMI) showed no signiﬁ-
cance. The logistic model, corrected for age-sex and severity
identiﬁed as associated factors: diabetes mellitus (OR = 2.1; 
CI = 1.3–3.4; p = 0.001) and dyslipidemia (OR = 1.7; CI =
1.1–2.7; p = 0.002). Quantiﬁcation of unit cost/year/COPD was
€2793.22 ± 3166.30 (70.5% pharmaceutical expenditure). The
cost/year/patient-adjusted was €2847.22 (SE = 117.02) without
CVEs, versus €2563.66 (SE = 244.05) with CVEs, p = NS. CON-
CLUSIONS: The presence of CVEs associated with COPD is
high, causing an important co-morbidity, though without
increasing the global costs of the disease. Diabetes mellitus and
dyslipidemia are the main CVRFs associated; their prevention
could improve the disease outcomes. Further studies are needed
to conﬁrm the consistency of these results.
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OBJECTIVES: In The Netherlands, costs of statin use have
recently increased sharply compared to costs of other drugs. Yet,
several studies have established undertreatment and overtreat-
